慢性进行性多发性硬化症(MS)是一种严重的脱髓鞘疾病,其中有自身免疫过程起着主要作用。核苷药物Cladribine是一种强力淋巴细胞因子,副作用小,本文通过随机双盲试验测定用Cladribine治疗MS的安全性和效果。 患者51例,其中48例按年龄、性别和病情配成24对,给予0.7mg/kg Ccladribine或安慰剂治疗4个月,通过手术植入给药,每月体检并记录Kurtzke和Scripps计分。患者在6个月和12个月时做脑脊液和核磁共振影像(MRI)检查。结果,接受Cladribine治疗的患者其平均神经病学计分、MRI示脱髓鞘范围及脑脊液中寡克隆带密度均不 Chronic progressive multiple sclerosis (MS) is a serious demyelinating disease in which an autoimmune process plays a major role. The nucleoside drug Cladribine is a potent lymphokine and its side effects are small. We tested the safety and efficacy of Cladribine in the treatment of MS by a randomized double-blind trial. Fifty-one patients were enrolled, of whom 48 were matched by age, sex and condition, and were treated with 0.7 mg / kg Ccladribine or placebo for 4 months. The patients were surgically implanted and scored monthly for Kurtzke and Scripps scoring. Patients underwent cerebrospinal fluid and magnetic resonance imaging (MRI) at 6 months and 12 months. As a result, patients who received Cladribine had mean neurological scores, MRI demyelination range, and oligoclonal band density in cerebrospinal fluid